M3/M4 Course Offerings
2024-2025 M3/M4 Course Syllabi
Internal Medicine
COURSE NUMBER:
07 11 01
TITLE:
ENDOCRINOLOGY/METABOLISM -IM -ICE
This elective provides a broad exposure to inpatients and outpatients with endocrine diseases. The student will see patients at the VA Medical Center and the University of Cincinnati Medical Center. Students will see patients with Type 1 and Type 2 diabetes mellitus, pituitary disorders, thyroid and parathyroid disorders and disorders of calcium metabolism, adrenal disease as well as other disorders of the endocrine system. Student will need to complete full VA onboarding prior to starting the course.
PREREQUISITES:
26931373 (INTERNAL MEDICINE CORE CLKSP), 26931373 (INTERNAL MEDICINE CORE CLKSP)

Successfully complete the Internal Medicine Core Clerkship and complete full VA onboarding.
expand all

GENERAL INFORMATION

COURSE YEAR:
M4
CREDIT HOURS:
8
CREDIT WEEKS:
4
DOMESTIC VISITING:
NO
INTERNATIONAL VISITING:
NO
GRADED:
Honors/High Pass/Pass/Fail
COURSE QUALIFICATIONS:
ICE
STATUS:
Full-Time   
OFFERED AS FULL-TIME AND PART-TIME: NO
ALLOWS OVERLAP: NO
COURSE LENGTH:
4 wks
DIRECTOR:
Abid Yaqub, MD
yaqubad@ucmail.uc.edu

ADMINISTRATIVE SUPPORT PERSON:
Gabriela Ionascu
ionascgi@ucmail.uc.edu
513-558-2592
MSB, 6055A
SITE(S):
UCMC - University of Cincinnati Medical Center
VAMC
MAX ENROLL:
2 
ROTATIONS:
Rotation Dates Max
1 05/06/2024 - 05/31/2024 2
2 06/03/2024 - 06/28/2024 2
3 07/01/2024 - 07/26/2024 2
4 07/29/2024 - 08/23/2024 2
5 08/26/2024 - 09/20/2024 2
6 09/23/2024 - 10/18/2024 2
7 10/21/2024 - 11/15/2024 2
8 11/18/2024 - 12/13/2024 2
9 12/16/2024 - 01/10/2025 0
10 01/13/2025 - 02/07/2025 2
11 02/10/2025 - 03/07/2025 2
12 03/10/2025 - 04/04/2025 2
13 04/07/2025 - 05/02/2025 2

NOTE: If a rotation is offered in both 2 and 4 week slots, the max capacity is limited to the actual spots offered for the 4 weeks. (ie: the 2 week rotations listed share the max of the 4 week rotation)
WORKING HOURS:
8:00 am - 5:00 pm, Monday - Friday
REPORT 1ST DAY:
Will get email with directions prior to first day.

INSTRUCTION

LEARNING ACTIVITIES:
  • Case-Based Instruction/Learning
  • Clinical Experience - Inpatient
  • Conference
  • Demonstration (description, performance, or explanation of a process, illustrated by examples, observable action, specimens, etc)
  • Patient Presentation--Faculty
  • Patient Presentation--Learner
  • Self-Directed Learning (Learners take initiative for their own learning; diagnosing needs; formulating goals; identifying resources; implementing appropriate activities; and evaluating outcomes.)
  • Ward Rounds
LEARNING ENVIRONMENT POLICIES:
UCCOM strives to provide medical students with a learning environment that is conducive to their professional growth. All UCCOM and visiting medical students are encouraged to review the Student Handbook.

The Office of Student Affairs and Admissions is available to all UCCOM and visiting medical students to discuss any concerns/questions related to the learning environment. Please call 558-6796 to access faculty/staff that can assist you.
TEACHING:
50% Attending Physician
50% Fellow Physician
FEEDBACK:
ASSESSMENT:

ASSESSMENT METHODS:
Clinical Performance Rating/Checklist
Narrative Assessment
FINAL GRADE:
GRADE ASSIGNED BY: Course director

OBJECTIVES

Curricular Resources :
Textbooks:
  1. Gardner DG, Shoback D, eds. Greenspan's Basic & Clinical Endocrinology. 10th ed. New York, NY: McGraw-Hill Education; 2018
  2. Melmed S, Koenig R, Rosen C, Auchus R, Goldfine A, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Saunders; 2019
  3. Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, Potts JT Jr, Weir GC, eds. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia, PA: Elsevier Saunders; 2010.
  4. Rosen CJ, Bouillon R, Compston JE, Rosen V, eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8th ed. Washington, DC: Wiley-Blackwell; 2013.
  5. Braverman LE, Cooper D, eds. Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2013.
  6. Bilezikian JP, editor-in-chief. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 9th ed. Washington, DC: Wiley-Blackwell; 2018.
  7. Kopp P ed. Endotext. Endotext.org (A comprehensive online Endocrine Textbook)
Articles Reading List:

Thyroid:
  1. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252-265.
  2. Biondi B, Cooper DS. Subclinical Hyperthyroidism. N Engl J Med. 2018 Jun 21;378(25):2411-2419.
  3. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421.
  4. Burch H, Cooper D. Management of graves’ disease. A review. JAMA 2015; 314(23) 2544-2554.
  5. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433-512.
  6. Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751.
  7. Peeters RP. Subclinical Hypothyroidism. N Engl J Med. 2017 Jun 29;376(26):2556-2565.
  8. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1-133.
  9. Nishino M, Nikiforova M. Update on molecular testing for cytologically indeterminate thyroid nodules. Arch Pathol Lab Med 2018; 142: 446-47.
  10. Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European Thyroid Association guidelines for the treatment and follow up of advanced radioiodine refractory thyroid cancer. Eur Thyroid J 2019; 8(5): 227-245.
  11. Wells SA Jr, Asa SL, Dralle H, et al; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610.
  12. Fliers E, Bianco AC, Langouche L, Boelen A. Endocrine and metabolic considerations in critically ill patients. Thyroid function in crtically ill patients. Lancet Diabetes Endocrinol 2015; 3(10): 816-825.
  13. Burch H. Drug effects on the thyroid. N Engl J Med 2019; 381 (8); 749-671.
  14. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid
  15. Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar;27(3):315-389.
Diabetes Mellitus:
  • Standards of Medical Care in Diabetes—2022 American Diabetes Association. Diabetes Care 2020. Jan; 45 (Supplement 1): S1-264.
               o  S14: Classification and Diagnosis of Diabetes
               o   S83: Glycemic targets
               o   S97: Diabetes technology
               o   S125: Pharmacologic approaches to glycemic management
               o   S144: Cardiovascular disease and risk management
               o   S175: Chronic Kidney Disease and risk management
               o   S185: Retinopathy, neuropathy, and foot care
               o   S232: Management of diabetes in pregnancy
               o   S244: Diabetes care in the hospital

  • Perioperative Hyperglycemia Management: An Update. Duggan EW, Carlson K, Umpierrez GE. Anesthesiology. 2017 Mar;126(3):547-560.
  • Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23;139(17):2022-2031.
  • SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Lancet. 2019 Jan 5;393(10166):31-39.
  • ACCORD Study Group: Effects of intensive glucose lowering in Type 2 Diabetes. N Engl J Med 2008; 358:2545-2559
  • ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560- 2572.
  • Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073-1781.
  • Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes. Endocr Rev. 2008;29(3):292-302.
  • S. Amed, R. Oram Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment, Can J Diabetes 40 (2016) 449–454
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes [published correction appears in BMJ. 1999;318(7175):29]. BMJ. 1998;317(7160):703-713.
  • The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
Bone and Mineral Metabolism:
  • Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015 Jun 2;350:h2723
  • Insogna KL. Primary Hyperparathyroidism. N Engl J Med. 2018 Sep 13;379(11):1050-1059
  • Bollerslev J, Pretorius M, Heck A. Parathyroid hormone independent hypercalcemia in adults. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):621-638
  • Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):609-61
  • Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM. Hypoparathyroidism. Nat Rev Dis Primers. 2017 Aug 31;3:1705
  • Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020 Mar 1;105(3)
  • Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-2381.
  • Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016 Jan 21;374(3):254-6
  • Watts NB, Adler RA, Bilezikian JP, et al Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802-1822. Buckley L, Humphrey MB. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018 Dec 27;379(26):2547-2556
  • Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-39
  • Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep. 2014;12(4):385-395.
  • Khan AA, Morrison A, Hanley DA, et al; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23
  • Mirza F, Canalis E. Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131-R151
  • Bronson WH, Kaye ID, Egol KA. Atypical femur fractures: a review. Curr Osteoporos Rep. 2014;12(4):446-453
  • Bover J, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017 Oct;30(5):677-687
  • Christov M, Jüppner H. Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):685-706
  • Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, Volume 96, Issue 7, 1 July 2011, Pages 1911–1930
Pituitary Disease:
  • Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatement of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288
  • Katznelson L, Laws ER Jr, Melmed S. Acromegaly: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951
  • Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609
  • Silveira LF, Latronico AC. Approach to the patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013;98(5):1781-1788
  • Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011;96(4):905-912
  • Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540.
  • Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100: 2807–2831, 2015
  • Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921
  • Oiso Y, Robertson GL, Norgaard JP, Juul KV. Clinical review: treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab. 2013;98(10):3958-3967
  • Briet C, Salenave S, Bonneville JF, Laws E, Chanson P. Pituitary Apoplexy. Endocrine Reviews. 2015; 36(6): 622–645
  • Khan S, Salvatori R. The Perioperative and Postoperative Care for Pituitary Patients. Chapter in Transsphenoidal surgery, Complication Avoidance and Management Techniques. Laws E, et al. (2017).
  • Ergin AB, Kennedy AL, Gupta MK, Hamrahian AH. The Cleveland Clinic Manual of Dynamic Endocrine Testing. New York, NY: Springer; 2015.
Adrenal Disorders:
  • Zavatta G, Di Dalmazi G. Recent Advances on Subclinical Hypercortisolism. Endocrinol Metab Clin North Am. 2018;47(2):375-383
  • Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3(3):216-226
  • Betterle C, Morlin L. Autoimmune Addison's disease. Endocr Dev. 2011; 20:161-172.
  • Grossman AB. Clinical Review#: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab. 2010;95(11):4855-4863
  • Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012;76(1):21-25
  • Funder JW, Carey RM, Fardella C, et al; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266-3281.
  • Torre JJ, Bloomgarden ZT, Dickey RA, et al; AACE Hypertension Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension [published correction appears in Endocr Pract. 2008;14(6):802- 803]. Endocr Pract. 2006;12(2):193-222.
  • Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-S42.
  • Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 2011;40(2):333-341
  • Phyllis W. Speiser,1,2 Wiebke Arlt,3 Richard J. Auchus et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 103: 4043–4088, 2018
  • Vaidya A, Hamrahiyan A, Bancos I, Fleseriu M, Ghayee HK. The Evaluation of Incidentally Discovered Adrenal Masses. Endocrine Practice. 2019; 25(2):178-192
  • Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942
  • Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151-160

Reproduction and Sexual Function:

Female:
  • Silveira LF, Latronico AC. Approach to the patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013;98(5):1781-1788.
  • Gordon CM, Kanaoka T, Nelson LM. Update on primary ovarian insufficiency in adolescents. Curr Opin Pediatr. 2015;27(4):511-519.
  • Torrealday S, Pal L. Premature menopause. Endocrinol Metab Clin North Am. 2015;44(3):543- 557.
  • Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44-e50.
  • Gravholt CH, Viuff MH, Brun S, Stochholm K, Andersen NH. Turner syndrome: mechanisms and management. Nat Rev Endocrinol. 2019 Oct;15(10):601-614.
  • McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54-64. Article Teede HJ, et al.; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018 Aug;110(3):364-379.
  • Martin KA, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab. 2018;103(4):1-25.
  • Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975- 4011.
  • Torrealday S, Pal L. Premature menopause. Endocrinol Metab Clin North Am. 2015;44(3):543- 557. Article Santen RJ, Kagan R, Altomare CJ, Komm B, Mirkin S, Taylor HS. Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. J Clin Endocrinol Metab. 2014;99(3):733-747.
Male:
  • Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250-1263.
  • Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744.
  • Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013 Jan 12;381(9861):153-65.
  • Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol. 2014;10(11):684-698.
  • Kathrins M, Niederberger C. Diagnosis, and treatment of infertility-related male hormonal dysfunction. Nat Rev Urol. 2016;13(6):309-323.

Gender Incongruence:
  • Safer JD, Tangpricha V. Care of the Transgender Patient. Ann Intern Med. 2019;171(1):ITC1- ITC16.
  • Hembree WC, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102(11): 3869-3903
Instructional Methods:
  • Clinical Experience--Ambulatory
  • Clinical Experience - Inpatient
  • Discussion-Small Group (Small Group (=12)
  • Independent Learning
  • Patient Presentation--Learner
  • Ward Rounds
Knowledge/Skills:
  1. Perform a critical history and physical examination on patients with endocrine/metabolic problems.
  2. Develop a concise differential diagnosis.
  3. Select and interpret diagnostic tests for common endocrine conditions including thyroid, adrenal, pituitary, gonadal, bone, lipid disorders, and diabetes.
  4. Describe the relevant pathophysiology of the more common endocrine/metabolic diseases including diabetes mellitus, thyroid hypo- and hyperfunction, disorders of calcium metabolism and pituitary and adrenal disease, and explain clinical presentation of patients in terms of the pathophysiology.
  5. Display knowledge of systematic approaches to conditions encountered less frequently but applicable across the spectrum of endocrine disease and organ systems which depend upon negative feedback regulation. These may include such conditions as multiple endocrine neoplasia and polyendocrine failure syndromes, pheochromocytoma, peptide or steroid hormone producing tumors or congenital adrenal hyperplasias.
  6. Be familiar with preventive strategies in management of other chronic endocrine/metabolic diseases.
Main Course Topics :
  1. Endocrine hyper- and hypo-function and endocrine neoplasms, pathophysiology and workup, affecting: pituitary, thyroid, parathyroids, endocrine pancreas, adrenals, testes, ovaries.
  2. Diabetes Mellitus: Theory and practical management of glycemic control, hypoglycemia, chronic complications of diabetes
  3. Thyroid Disease: Thyroid function testing, hypothyroidism, hyperthyroidism, euthyroid sick syndrome, thyroid nodules, thyroid cancer
  4. Mineral Metabolism and Metabolic Bone Disease: Hypercalcemia, hypocalcemia, osteopenia, calcium nephrolithiasis
  5. Hirsutism
Procedures:
  1. Become familiar with finger stick blood glucose testing, continuous glucose monitoring systems (CGMS) and insulin pump, insulin pens and other insulin delivery devices.  
  2. Participate in endocrine dynamic tests as the opportunity arises on their patients. These may include such tests as ACTH stimulation testing, Glucagon stimulation testing, metyrapore tests, dexamethasone suppression testing, oral glucose tolerance testing (OGTT) and 72 hour fast for hypoglycemia.
  3. Observe and/or participate in thyroid ultrasound exams and fine needle aspiration (FNA)biopsy of thyroid nodules.
Remediation Plan:
 N/A

SAMPLE WEEK

Monday:
7:30AM 12:00PM Diabetes & Endo Clinic, VAMC 4th Floor
12:30PM 5:00PM Consult Rounds, UCMC
Tuesday:
7:30AM 12:00PM Dr. Jana Clinic, MAB 6th Floor
12:30PM 5:00PM Consult Rounds, UCMC
Wednesday:
7:30AM 12:00PM Dr. Carracher Endo Clinic, MAB 6th Floor
12:30PM 5:00PM Consult Rounds, UCMC
Thursday:
7:30AM 12:00PM Diabetes & Endo Clinic, VAMC 4th Floor
12:30PM 5:00PM AHD (optional) and/or Consult Rounds, UCMC
Friday:
7:30AM 12:00PM Consult Rounds, UCMC
12:30PM 5:00PM Endo Conferences & Consult Rounds, UCMC
SCHEDULE NOTE:

Detailed Schedule & Conference information emailed prior to starting the elective.

ATTENDANCE AND ABSENCE POLICY

 

Session Attendance for M4 Students

  • Students may miss no more than two days of planned excused absences on a four week rotation without being required to make-up the work, at the discretion of the clerkship/elective/course director or his/her designee.
  • Non-AI Rotations - Per the Student Duty Hours Policy, an average of one day (24 hours) in every seven must be free of clinical responsibilities (including seminars, clinic, rounds, lectures) averaged over a four week period. These days off are assigned by the clerkship director to best align with the site schedule. Students may request to schedule 1 or more of these 4 days for planned absences that fall under 1 of the categories listed below for excused absences during non-AI rotations, in consultation with the course/elective director, who may or may not approve such planned absences.
  • AI Rotations - Per the Student Duty Hours Policy, an average of one day (24 hours) in every seven must be free of clinical responsibilities (including seminars, clinic, rounds, lectures) averaged over a four week period. These days off are assigned by the course director to best align with the site schedule. Students may request to schedule 1 or 2 of these days for planned absences that fall under 1 of the categories listed below for excused absences during AI rotations, in consultation with the course director, who may or may not approve such planned absences. Students must avoid scheduling Step 2 examinations during an Acting Internship.
  • Excused Absences - The following will be considered excused absences:
    • Diagnostic, preventative, and therapeutic health services (e.g. doctor appointments, physical therapy, counselling, etc).
    • Personal illness, accident or a major catastrophic event
    • Death or serious illness of immediate family members. Immediate family members, as defined by UC, are Grandparents, Brother, Sister, Brother-in law, Sister-in-law, Daughter-in-law, Son-in-law, Father, Mother, Mother-in-law, Father-in-law, Step-sister, Step-brother, Step-mother, Step-father, Spouse or domestic partner, Child, Grandchild, legal Guardian or other person who stands in place of parent (in Loco Parentis)
  • Whenever possible, planned absences should be requested a minimum of six weeks in advance of the start of the clerkship/elective/course in which the absence will occur; this enables the clerkship/course/elective to help plan for educational event scheduling (e.g. a known appointment could be scheduled around with enough notice and the student might not have any required coursework to make up). Absences requested less than 1 week prior to the planned absence may not be considered for a possible excused absence unless extenuating circumstances prevented the student from providing timely notification per the policy. Students should first submit their request for a planned absence to the clerkship/elective/course director using the online MSSF. All planned/excused absences for any reason should be documented on the MSSF.
  • The COM abides by the UC Religious Observance Policy that respects the religious diversity of its students by providing opportunities, where possible, for accommodation in cases where conflicts exist between students’ religious beliefs/practices and educational activities. In clinical settings, such accommodations must honor the primacy of a commitment to patient care and avoid unduly burdening faculty, staff and the general student population involved in the affected educational and/or patient care activity.
  • The following items are explained in detail in the Medical Student Handbook:
    • Excused/unexcused/unplanned absence, religious holidays, jury duty, and make-up work

See Attendance and Absences Policy, Religious Observance Policy, Medical Student Handbook.




University of Cincinnati College of Medicine | MedOneStop | Contact Us
Alerts | Clery and HEOA Notice | Notice of Non-Discrimination | eAccessibility Concern | Privacy Statement | Copyright Information
© 2024 University of Cincinnati